Superworth

Avalo Therapeutics price to book ratio AVTX

Market value divided by the book value of the company's net assets, since 2016.

Today, Nov 2, 2026
0.9×
10-year median
5.9×
Against its 10-year history
9th
percentile: 0 is its lowest day, 100 its highest
10-year range
0.2× to 81.0×
Peer median
2.0×

Avalo Therapeutics' price to book ratio is 0.9× as of Nov 2, 2026.

That is below its ten-year median of 5.9×, lower than on 91% of days in the last ten years.

Over that time it ranged from 0.2× in Jan 2024 to 81.0× in Nov 2016.

The median for 10 large drugmakers of a similar size is 2.0×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far0.9×0.8×14.9×
20253.6×0.3×4.2×
20244.1×0.2×6.6×
20230.5×0.5×1.2×
20225.3×2.0×9.4×
20214.7×4.7×13.4×
20205.1×3.1×12.2×
201912.4×6.7×12.9×
20186.6×3.2×8.5×
20173.8×1.2×40.9×
201613.9×2.2×81.0×

Against its peers

Companies in Drug Manufacturers - General nearest Avalo Therapeutics' size, closest first, today.

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Avalo Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.